Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or "the Company") has announced it will continue with recruitment for its world-first Phase III insomnia program following a positive interim analysis ...
The Drug Enforcement Administration is considering a proposal to move marijuana from Schedule I to Schedule III of the ...
14h
Melatonin can be a safe and effective sleep aid for all ages but improper dosing leads to real harms
Melatonin—a go-to sleep aid for kids and adults alike in many households in America—continues to create media buzz, with ...
8h
South Korea designates 7 new regulatory-free zones to fast-track hydrogen, medical cannabis projects
The commercialization of new technologies — including hydrogen power generation, industrial cannabis cultivation and fuel ...
Amazon S3 on MSN
CBD lotion tied to reduced skin damage from UV rays
A groundbreaking study suggests that applying CBD-infused lotion to the skin may reduce the risk of damage from ultraviolet ...
Indiana's hemp businesses are thriving through a federal Farm Bill loophole but a Statehouse push to crack down on THC ...
Allen R. Voigt, founder and CEO of EndoPure Life Sciences, believes that trust has become the defining issue for the next ...
Avecho shares today entered trading halt, pending the release of results for the company's synthetic cannabinoid phase III ...
A new report reveals that both cannabis employment and revenue have dropped for the first time since legal adult-use cannabis ...
How can cannabis be used to fight acne and other skin inflammation? This is what a recent study published in the journal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results